Background
As the fourth most common cause of cancer-related deaths globally [
1], colorectal cancer (CRC) is a major public health burden in most industrialized countries [
2]. The poor efficiency and lack of options for treating metastasis is the major cause of death due to CRC. Specifically, the 5-year survival rate is 90.3% for patients with local disease, whereas it declines to 70.4 and 12.5% for patients with regional and distant metastasis, respectively [
3]. Although great achievements have been made in medical science and technology over the last few decades, the understanding of the mechanisms underlying CRC development is still limited. It is imperative to explore the molecular events in CRC metastasis, which remains as one of the most difficult challenges encountered by modern oncologists.
In our previous study [
4], we analyzed the gene expression profiles of paired tumor and normal tissue samples from The Cancer Genome Atlas (TCGA) datasets, and identified a number of genes that are significantly up-regulated or down-regulated in different types of cancer compared to their normal counterparts. Among them, we focused on Angiopoietin-like protein 1 (ANGPTL1), which was down-regulated in 87.5% (14/16) of included cancer types. ANGPTLs are a family of proteins that are structurally similar to angiopoietins, comprising ANGPTL1 to ANGPTL7. Members of this family contain a coiled-coil domain and a fibrinogen-like domain and are able to regulate angiogenesis. However, they do not bind to the receptors classically targeted by angiopoietins and are orphan ligands with no known receptors. More recent studies have proposed that they are involved in various pathologies, such as disorders of lipid and glucose metabolism, inflammation, hematopoiesis, and cancer [
5,
6].
An early study showed that low expression of ANGPTL1 in lung and breast cancer tissues correlated with advanced-stage, higher grade tumor and lymph node status and poorer prognosis [
7]. Further investigation revealed that ANGPTL1 suppressed SLUG-dependent epithelial-mesenchymal transition (EMT), thereby suppressing migratory and invasive capabilities of lung and breast cancer cell lines [
7]. In addition, ANGPTL1 has been reported to inhibit the proliferation, migration, tube formation and adhesion of endothelial cells by blocking the MAPK and PI3K/Akt signaling pathways [
8,
9]. Taken together, these findings suggest that ANGPTL1 may act as a novel tumor suppressor candidate in lung and breast cancer. However, its effects on CRC cells remain poorly defined.
Therefore, in this study, we explored the expression of ANGPTL1 in CRC specimens and paired normal tissues to gain a better understanding of its biological role in CRC. We found that ANGPTL1 was down-regulated in CRC tissues, and its low expression indicated shorter survival. In vitro and in vivo experiments showed that ANGPTL1 suppressed migration and invasion of CRC cells and prolonged overall survival (OS) in mouse models, which may be mediated by the up-regulation of microRNA-138 (miR-138). Our present study demonstrated for the first time that ANGPTL1 suppressed CRC metastasis and may be a novel target for the treatment of CRC.
Methods
Mining of differentially expressed genes
Expression data for ANGPTL1 in CRC and additional cancer types were extracted from level 3 TCGA RNA-seq data, totaling 705 paired tumor and normal samples. To determine the key differentially regulated genes between paired cancer and normal tissues, we compared gene expression profiles between cancer and normal groups by DEGSeq package for R/Bioconductor, and the P value was adjusted according to the false discovery rate. In addition, the relationship between the ANGPTL1 expression and its clinical manifestations was validated by publicly available independent microarray datasets (GSE32323 and GSE24550).
Furthermore, the GSE29623 and GSE35982 datasets, with information on both mRNA and microRNA (miRNA), were used to identify differentially expressed miRNA between high-ANGPTL1 and low-ANGPTL1 groups. All expression profiling data in this study were downloaded from TCGA (
http://cancergenome.nih.gov/) and the Gene Expression Omnibus (GEO) (
http://www.ncbi.nlm.nih.gov/geo/). We were able to use these databases by meeting the freedom-to-publish criteria of TCGA and NCBI.
Patients and specimens
Tumor tissue samples and paired normal mucosal tissue were obtained by surgical resection and stored at −80 °C from 2009 to 2014 at the Second Affiliated Hospital of Zhejiang University, School of Medicine. Two pathologists confirmed these tissue samples as colorectal adenocarcinoma. This project was approved by the ethical committee of the Second Affiliated Hospital of Zhejiang University, School of Medicine and informed consent was obtained from all patients.
Cell culture and reagents
All cells were cultured in RPMI-1640 (Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum (Life Technologies, Carlsbad, CA, USA) at 37 °C in a humidified atmosphere with 5% CO2. All cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA). The lentiviral particles containing shRNA directed against ANGPTL1 (sc-88171-V) and corresponding scramble control (sc-108080) were purchased from Santa Cruz Technologies (Santa Cruz, CA, USA), and lentivirus containing firefly luciferase was purchased from Hanbio Biotechnology (Shanghai, China). miR-138 inhibitor, mimics and negative controls were synthesized by GenePharma (Shanghai, China) and were dissolved in DEPC-treated H2O.
Lentivirus production and infection
The lentiviral vectors for ANGPTL1 were purchased from Cyagen Biosciences (Guangzhou, China), including pLV (Exp)-Puro-CMV > hANGPTL1/HA-IRES-eGFP and its control vector, pLV (Exp)-Puro-CMV > IRES-eGFP. One night prior to transfection, 293 T cells were plated in DMEM (Gibco) supplemented with 10% FBS without antibiotics. On the day of infection, the cells were transfected with a mixture of ANGPTL1 expression lentivector and pLV/helper packaging plasmids mix using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The medium was replaced after overnight transfection. Supernatants were collected at 48 h post transfection, and filtered through 0.45 μm filters to remove cells and debris. Thus, the lentiviruses containing ANGPTL1/HA cDNA and the corresponding scramble control were harvested [
10].
For lentiviral infection, cells were plated at 60–70% confluence. On the second day, the culture medium was replaced with complete medium containing appropriate lentiviral particles (MOI = 20) and Polybrene (2–5 μg/ml). Following 24 h of infection at 37 °C, the viral supernatant was replaced with fresh media. Another 48 h later, the infected cells were treated with 2.0 μg/ml puromycin dihydrochloride (Santa Cruz) for 2 weeks for selection of stable clones. The overexpression and knockdown efficiency was determined by quantitative real-time PCR (qPCR) and western blot (WB) analyses.
Transfection of miRNA inhibitor or mimics
We transfected cells with a miRNA inhibitor or mimics using Lipofectamine 2000 according to the manufacturer’s instructions. Cells were seeded in 6-well plates and allowed to reach 60–70% confluence prior to transfection. The final concentration of the miR-138 inhibitor or mimics and their corresponding negative controls was 50 nmol/l. Twenty-four hours later, cells were harvested to evaluate the transfection efficiency. Then, successfully transfected cells were used for the following experiments.
For miR-138 inhibitor, the single-stranded RNA sequence was 5′-CGGCCUGAUUCACAACACCAGCU-3′. 5′- CAGUACUUUUGUGUAGUACAA-3′ was the sequence of its corresponding negative control. For miR-138 mimics, the sequences of oligonucleotides were 5′-AGCUGGUGUUGUGAAUCAGGCCG-3′ (sense), and 5′-GCCUGAUUCACAACACCAGCUUU-3′(antisense). And the sequences were 5′-UUCUCCGAACGUGUCACGUTT -3′(sense) and 5′- ACGUGACACGUUCGGAGAATT-3′ (antisense) for its negative control.
qPCR
Total RNA from cells and fresh human tissues was isolated using RNAiso reagent (Takara Biotechnology, Dalian, China) according to the manufacturer’s instructions. The quality and quantity of RNA were evaluated using NanoDrop 1000 spectrophotometer (Thermo Scientific, Pittsburgh, PA, USA). cDNA was synthesized with PrimeScript™ II 1st Strand cDNA Synthesis Kit (Takara Biotechnology). To validate the mRNA expression profiles, qPCR was performed using a standard SYBR-Green PCR kit protocol (Takara Biotechnology) with the StepOne Plus Real Time PCR System (Life Technologies). The primers were synthesized by Sangon Biotech (Shanghai, China), and the sequences were as follows: ANGPTL1 forward: 5′-CAACATATTCCTAACAGCCAACAG -3′, reverse: 5′-TGACAGTCTTTGAATGGTCCTTC -3′; GAPDH forward: 5′- TCTCTGCTCCTCCTGTTCGA -3′, reverse: 5′- GCGCCCAATACGACCAAATC -3′. All PCR reactions were performed in triplicate. GAPDH was used as an internal control.
For quantifying mature miR-138, reverse transcription was performed using a miRNA 1st Strand cDNA Synthesis kit (Sangon Biotech, Shanghai, China) according to the manufacturer’s protocol. The reverse transcription primer for miR-138 was 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCGGCCT-3′, and primer for small nuclear RNA U6 was 5′- GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAAATA-3′. The mature miR-138 level was normalized with U6 determined by qPCR, as described previously. Primers sequences were as follows: miR-138 forward: 5′-AAGCGGAGCTGGTGTTGTGAATC-3′, reverse: 5′- ATCCAGTGCAGGGTCCGAGG-3′; U6 forward: 5′-AGAGAAGATTAG CATGGCCCCTG-3′, reverse: 5′-ATCCAGTGCAGGGTCCGAGG-3′.
WB analysis
WB analysis was performed as described previously [
11]. Briefly, cell protein was extracted using Mammalian Protein Extraction Reagent (Thermo Scientific, Pittsburgh, PA, USA) supplemented with 1% protease inhibitor cocktails (Sigma-Aldrich, Hamburg, Germany). Protein concentration was measured using a BCA protein assay kit (Thermo Scientific). The protein samples (10–20 μg) were separated by 12% SDS-PAGE, transferred to a PVDF membrane (Bio-Rad, Hercules, CA, USA) and then detected with appropriate primary and secondary antibodies. Protein bands were visualized by chemiluminescence (Thermo Scientific) and scanned via a Kodak Image Station (Carestream Health, Inc., Rochester, New York, USA). The primary antibodies used were goat anti-ANGPTL1 polyclonal antibody (1:1000, R&D Systems, Minneapolis, MN, USA) and rabbit anti-GAPDH monoclonal antibody (1:1000, Cell Signaling Technology, Beverly, MA, USA).
Transwell migration and invasion assay
Cells resuspended in 200 μl serum-free medium were seeded in the upper chamber with 10% serum-containing medium in the lower chamber of 24-well transwell plates (Corning Inc., NY, USA). After 48 or 72 h, the non-invaded cells in the upper chamber were removed with cotton swabs, and HE staining solution was then used to stain the invaded cells. Images were taken at 10× or 20× magnification. In addition, cell numbers were counted in at least 5 random microscope fields. Matrigel-coated 8 μm-pore transwells (Corning Inc.) were used for the invasion assay. The procedures and analyses were the same as those for the transwell migration assay except for the presence of Matrigel.
Cell proliferation assay
Cell proliferation was analyzed using the Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories, Tokyo, Japan). Cells were seeded into 96-well plates at the density of 5 × 103 cells/200 μl per well. 20 μl CCK-8 solution will be added to cells in culture and incubated for 1 h. The absorbance of each well was measured using a microculture plate reader at a wavelength of 450 nm. Three replicate wells were set up in each group and three independent experiments were performed, respectively.
Five hundred cells were inoculated into the 6-well plate containing 3 mL medium, which was changed every 3 days. After 2 weeks, clone spheres were formed. Cells were rinsed with PBS, and then fixed with 4% paraformaldehyde for 15 min. Crystal violet was added for staining for 15 min, and the plates were rinsed with flow water, and then air-dried. The number of clones in each plate was counted.
Mice
Balb/c athymic nude mice (SLAC Laboratory Animal Co. Ltd., Shanghai, China) were maintained and subjected to the experiments in accordance with the protocols approved by the Second Affiliated Hospital of Zhejiang University School of Medicine Animal Care and Use Committee. All animal experiments were performed on 5 to 6 weeks old female Balb/c athymic nude mice.
Subcutaneously inoculated model
Tumor cells (1 × 106) were injected subcutaneously into mice. Three weeks after injection, the mice were euthanized, and the tumors were excised. Long (L) and short (S) axes of each tumor were measured with calipers. Tumor volume (V) was calculated as follows: V = (LxS2)/2. In addition, tumor weight was also measured.
The CRC hemi-spleen liver metastasis model was established by using a previously described technique [
12]. Mice were anaesthetized and an incision was made between the left abdominal and thoracic regions, and the spleen was exposed. The spleens were divided into two halves, and the halves were clipped. In total, 2 × 10
6 cells were injected into the splenic vessels (splenic artery and veins) through one hemi-spleen followed by flushing with PBS. After the injection, the splenic vessels draining the injected hemi-spleen were clipped, and the hemi-spleen was removed. The abdominal wall and skin were sutured. Tumor metastasis was monitored using a small animal IVIS Lumina imaging system (Caliper Life Sciences, Hopkinton, MA) 15 min after intraperitoneal administration of D-luciferin (PekinElmer Inc., Boston, USA) at a concentration of 150 mg/kg. All mice were kept until death due to the neoplastic process or until the end of the experiment (2 months), and the livers were harvested for histological analysis of metastasis.
Orthotopic injection model
In brief, mice were anesthetized, and the cecum was exteriorized by laparotomy. A total volume of 50 μl cell suspension containing 5x10
6 tumor cells was injected into the cecal wall by a 26G needle. Then, the injection point was slightly pressed with a cotton stick and inspected to ensure that there was no leakage. Afterward, the cecum was returned to the abdominal cavity, and the skin was closed with running sutures [
13]. All mice were kept until death due to the neoplastic process or until the end of the experiment (3 months). Livers were harvested for histological analysis of metastasis.
Statistical analysis
All graphing and statistical analyses were performed using GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA, USA). The data are presented as the means ± standard errors of the mean. The gene expression and qPCR results from paired clinical samples were analyzed by two-tail paired Student’s t-test. The comparison of survival between groups was performed using the log-rank test, and Kaplan-Meier curves were plotted. The other results were analyzed by two-tail unpaired Student’s t-test. Pearson correlation analysis was used to measure the relationship between ANGPTL1 and miR-138. P values <0.05 indicated statistical significance.
Discussion
In this study, we compared the gene expression profiles of paired cancerous and normal tissues from TCGA datasets, and identified ANGPTL1 as a down-regulated gene in CRC. Further in vitro and in vivo studies confirmed that ANGPTL1 inhibited migration and invasion with limited effects on CRC cell proliferation and colony formation of CRC cells. Finally, we found that ANGPTL1 exerts its effect by up-regulating miR-138. This study is the first to investigate the role of ANGPTL1 in the biology and progression of CRC.
Similar to our results, previous studies have reported that ANGPTL1 was significantly decreased in lung [
7,
18] and breast [
7] tumor tissues compared to normal tissues. In addition, the inhibition of migration in CRC was consistent with the conclusions of a study by Kuo et al.[
7], in which ANGPTL1 was reported to inhibit the migration and invasion of lung and breast cancer cells via mesenchymal-epithelial transition. Together, these studies congruously characterized ANGPTL1 as a tumor suppressor gene in cancer.
miRNAs are involved in post-transcriptional and translational silencing of target genes by binding to complementary sequences in 3’ UTRs [
19]. Therefore, miRNAs are crucial in the regulation of many crucial biological processes, such as detachment, migration, invasion and colonization of cancer cells [
20,
21]. It has been reported that important signaling pathways in CRC, such as the Wnt/β-catenin, RAS, p53, TGF-β, NF-kB pathways, are regulated by miRNAs [
21‐
23]. A number of studies have demonstrated that miR-138 regulates various molecular pathways and is associated with initiation and progression of cancer, and thus is considered as a potential tumor suppressor [
24]. As reported by Jiang et al.[
25], ectopic transfection of miR-138 contributed to the reduced migration and invasion in oral tongue squamous cell carcinoma by targeting RhoC and ROCK2, which are involved in the remodeling of cellular cytoskeleton. In clear cell renal cell carcinoma cells, miR-138 reduced the expression of hypoxia-inducible factor-1 alpha, which in turn enhanced apoptosis and decreased cell migration [
26]. In addition, miR-138 was down-regulated in CRC tissues, and this down-regulation was associated with more severe metastasis in vitro and in vivo by targeting TWIST2 [
17]. Our results also confirmed that miR-138 expression is positively correlated with ANGPTL1 mRNA level in CRC tissues and is involved in ANGPTL1-induced attenuated migration of CRC cells, which was consistent with the reports of Long et al.[
17].
The transcription of miRNAs is carried out by RNA Polymerase II and controlled by RNA Polymerase II-associated transcriptional factors and multiple epigenetic factors. Following transcription, the pri-miRNA undergoes several steps of maturation, including Drosha and Dicer processing in the nucleus, Exportin 5-mediated nuclear export, and cytoplasmic processing [
19,
20]. Collectively, miRNAs are regulated at multiple levels. As reported by Kuo et al [
7], ANGPTL1 up-regulates miR-630 expression at the transcriptional level, thus leading to increase of both pre-miR-630 and pri-miR-630 expression. In this study, we found that miR-138 was up-regulated by ANGPTL1, but the mechanism of its biogenesis remains unexplored. As reported, epigenetic and transcription factors, as well as many other molecules, are correlated with miR-138 expression [
24]. For example, miR-138 expression can be decreased by methylation of its DNA [
27] and up-regulated by a histone deacetylase inhibitor [
28] and overexpression of P 19 H-Ras [
29]. ANGPTL1 might directly or indirectly regulate miR-138 expression via the above mechanisms.
With respect to the potential targets of miR-138, EMT, the TGF-β pathway, the RhoC-Erk-MMP-2/9 pathway, and the cofilin pathway have been identified to participate in the reduced migratory and invasive activity induced by miR-138 [
24]. Specifically, miR-138 overexpression inhibits EMT process by targeting Vimentin and EZH2, thus reducing breast cancer invasion [
30]. In CRC patients, miR-138 targets TWIST2, a crucial regulator of EMT, to attenuate metastasis [
17]. Because ANGPTL1 has also been reported to regulate EMT to attenuate metastasis [
7], it is likely that EMT might be a potential mechanism in the ANGPTL1-miR-138-induced inhibition of metastasis in CRC, which requires further exploration.
In summary, we provide clinical evidence that ANGPTL1 expression is down-regulated in CRC tissues and inversely correlated with survival in patients with cancer. We demonstrate that ANGPTL1 represses migration and invasion of CRC cells by up-regulating miR-138. Future studies are warranted to investigate the underlying mechanisms by which ANGPTL1 regulates the transcription of miR-138, and the target genes that are involved in the ANGPTL1-miR-138-induced inhibition of metastasis in CRC. Such studies will provide more insights into CRC and provide a rationale for the utilization of innovative therapy in targeting ANGPTL1 to improve CRC treatment.
Acknowledgements
Not applicable.